Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 43.00 | |
50 mg | In stock | $ 54.00 | |
100 mg | In stock | $ 79.00 | |
200 mg | In stock | $ 102.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 54.00 |
Description | Repaglinide (AG-EE 623ZW) is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes. Repaglinide has been linked to rare instances of clinically apparent acute liver injury. |
Synonyms | AG-EE 388 ZW, AG-EE 623ZW |
Molecular Weight | 452.59 |
Formula | C27H36N2O4 |
CAS No. | 135062-02-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 84 mg/mL (185.6 mM)
DMSO: 84 mg/mL (185.6 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Repaglinide 135062-02-1 DNA Damage/DNA Repair Membrane transporter/Ion channel Metabolism Potassium Channel PPAR mellitus. AG-EE 388 ZW AG-EE 623ZW inhibit Inhibitor benzoic type-2 insulin secretagogue CMBA diabetes acid carbamoylmethyl inhibitor